Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 350

1.

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL.

Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5820-5. Epub 2005 Apr 5.

2.

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL.

Mol Ther. 2009 Jun;17(6):1053-63. doi: 10.1038/mt.2009.17. Epub 2009 Feb 24.

3.

Sustained effects of nonallele-specific Huntingtin silencing.

Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S, Bonvento G, Brouillet E, Luthi-Carter R, Hantraye P, D├ęglon N.

Ann Neurol. 2009 Mar;65(3):276-85. doi: 10.1002/ana.21569.

PMID:
19334076
4.

Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.

Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL.

Mol Ther. 2014 Apr;22(4):797-810. doi: 10.1038/mt.2013.289. Epub 2014 Jan 6.

5.

Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.

McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, Davidson BL.

Mol Ther. 2011 Dec;19(12):2152-62. doi: 10.1038/mt.2011.219. Epub 2011 Oct 25.

6.

Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.

Stanek LM, Sardi SP, Mastis B, Richards AR, Treleaven CM, Taksir T, Misra K, Cheng SH, Shihabuddin LS.

Hum Gene Ther. 2014 May;25(5):461-74. doi: 10.1089/hum.2013.200. Epub 2014 Mar 21.

7.

Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.

Olson SD, Kambal A, Pollock K, Mitchell GM, Stewart H, Kalomoiris S, Cary W, Nacey C, Pepper K, Nolta JA.

Mol Cell Neurosci. 2012 Mar;49(3):271-81. doi: 10.1016/j.mcn.2011.12.001. Epub 2011 Dec 8.

8.

PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).

Ratovitski T, Arbez N, Stewart JC, Chighladze E, Ross CA.

Cell Cycle. 2015;14(11):1716-29. doi: 10.1080/15384101.2015.1033595.

9.

Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference.

Chen ZJ, Kren BT, Wong PY, Low WC, Steer CJ.

Biochem Biophys Res Commun. 2005 Apr 8;329(2):646-52. Erratum in: Biochem Biophys Res Commun. 2005 Jun 3;331(2):683.

PMID:
15737634
10.

High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo.

Huang B, Schiefer J, Sass C, Landwehrmeyer GB, Kosinski CM, Kochanek S.

Hum Gene Ther. 2007 Apr;18(4):303-11.

PMID:
17472569
11.

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.

12.

Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.

Wang YL, Liu W, Wada E, Murata M, Wada K, Kanazawa I.

Neurosci Res. 2005 Nov;53(3):241-9. Epub 2005 Aug 10.

PMID:
16095740
13.

AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D.

Mol Ther. 2008 May;16(5):947-56. doi: 10.1038/mt.2008.50. Epub 2008 Mar 25.

14.

Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.

Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, Lopez E, Myers RH, MacDonald ME, Wheeler VC.

Hum Mol Genet. 2006 Jun 15;15(12):2015-24. Epub 2006 May 10.

PMID:
16687439
15.

Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.

Southwell AL, Ko J, Patterson PH.

J Neurosci. 2009 Oct 28;29(43):13589-602. doi: 10.1523/JNEUROSCI.4286-09.2009.

16.

Towards a transgenic model of Huntington's disease in a non-human primate.

Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW.

Nature. 2008 Jun 12;453(7197):921-4. doi: 10.1038/nature06975. Epub 2008 May 18.

17.

Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.

DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, Manoharan M, Sah DW, Zamore PD, Aronin N.

Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17204-9. Epub 2007 Oct 16.

18.

Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.

McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, Zhou L, Pitzer MR, Berry-Kravis EM, Kordower JH.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9345-50. Epub 2006 Jun 2.

19.

Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.

Stanek LM, Yang W, Angus S, Sardi PS, Hayden MR, Hung GH, Bennett CF, Cheng SH, Shihabuddin LS.

J Huntingtons Dis. 2013;2(2):217-28. doi: 10.3233/JHD-130057.

PMID:
25063516
20.

Supplemental Content

Support Center